Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?
- 1 April 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Osteoporosis Reports
- Vol. 19 (2), 189-205
- https://doi.org/10.1007/s11914-021-00663-1
Abstract
Purpose of Review There are now three anabolic agents available for the treatment of postmenopausal women at high risk for fracture. The purpose of this review is to supply a rationale to aid in determining which agent should be used in which clinical settings. Recent Findings Studies over the last decade have shown that anabolic agents produce faster and larger effects against fracture than antiresorptive agents. Furthermore, trials evaluating anabolic antiresorptive treatment sequences have shown that anabolic first treatment strategies produce the greatest benefits to bone density, particularly in the hip region. However, there are no head-to-head evaluations of the three anabolic therapies with fracture outcomes or bone density, and these studies are not likely to occur. How to decide which agent to use at which time in a woman's life is unknown. We review the most significant clinical trials of anabolic agents which have assessed fracture, areal or volumetric bone density, microarchitecture, and/or bone strength, as well as information gleaned from histomorphometry studies to provide a rationale for consideration of one agent vs another in various clinical settings. There is no definitive answer to this question; all three agents increase bone strength and reduce fracture risk rapidly. Since the postmenopausal lifespan could be as long as 40-50 years, it is likely that very high-risk women will utilize different anabolic agents at different points in their lives.This publication has 120 references indexed in Scilit:
- Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifeneJournal of Bone and Mineral Research, 2012
- The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 yearsJournal of Bone and Mineral Research, 2012
- The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fracturesOsteoporosis International, 2011
- Issues in modern bone histomorphometryBone, 2011
- Parathyroid Hormone Stimulates Circulating Osteogenic Cells in HypoparathyroidismJournal of Clinical Endocrinology & Metabolism, 2011
- Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatideOsteoporosis International, 2010
- What old means to boneTrends in Endocrinology & Metabolism, 2010
- Outcome of prosthesis exchange for infected knee arthroplasty: the effect of treatment approachActa Orthopaedica, 2009
- Teriparatide or Alendronate in Glucocorticoid-Induced OsteoporosisThe New England Journal of Medicine, 2007
- Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnoverBone, 2006